

YPOG advises Aignostics on \$34 million Series B financing round

Berlin, October 30, 2024 - YPOG advised global artificial intelligence (AI) company Aignostics on its latest \$34 million Series B financing round. The round was led by ATHOS, with investments from the Mayo Clinic and growth financing from HTGF. It also received investments from existing investors including Wellington Partners, Boehringer Ingelheim Venture Fund, CARMA Fund, and the VC Fonds Technologie managed by IBB Ventures. Aignostics has raised more than \$55 million to date, demonstrating investor confidence in its unique AI models and well-defined commercial strategy.

Started in 2018, Aignostics was initially founded as a spin-off from Charité and Berlin Institute of Health in 2020. The AI company turns complex multimodal pathology data into transformative insights.

Following the closing of the latest financing round, Aignostics plans to create new products for biopharmaceutical clients, drive growth in the United States, and develop advanced foundation models for pathology in collaboration with Mayo Clinic. The new funding will enhance Aignostics' capabilities in target identification, translational research, and companion diagnostics (CDx), while also backing various strategic initiatives.

"2024 has been a pivotal year for us that has included a major strategic collaboration with Bayer and the launch of our first foundation model, RudolfV," says Viktor Matyas, CEO and Co-Founder of Aignostics. "With RudolfV, we've gained the ability to quickly develop cost-efficient algorithms that generalize to the real-world. Now with this new round of funding, we're turning our most popular algorithms into products that will help usher in an era of truly generalizable AI for computational pathology."

Team

<u>Dr. Martin Schaper</u> (Lead, Corporate/Transactions), Partner, Berlin <u>Dr. Jonas von Kalben</u> (Transactions), Senior Associate, Berlin <u>Anja Schindler</u> (Transactions), Senior Associate, Berlin <u>Benedikt Kreuder</u> (Transactions), Senior Associate, Berlin <u>Dr. Jacob Schreiber</u> (Transactions), Senior Associate, München

About Aignostics

Aignostics is an artificial intelligence (AI) company that turns complex multimodal pathology data into transformative insights. By combining proprietary access to multimodal clinical data, industry-leading technologies, and rigorous science, Aignostics develops best-in-class products and services for the next generation of precision medicine. Through collaborations with its biopharma partners, Aignostics supports drug discovery, translational research, clinical trials, and CDx development. Established in 2018, Aignostics is a spin-off from Charité Berlin, one of the world's largest and most esteemed university hospitals. Aignostics is funded by leading investors and has operations in Berlin and New York. Further information at <u>aignostics.com</u>

About YPOG

YPOG is a law firm specialized in tax and business law, active in the core fields of Funds, Tax, Banking + Finance, and Transactions. The team at YPOG represents a broad client base, which ranges from emerging technology companies and family-run SMEs to large corporations, as well as private equity, and venture capital funds. YPOG is one of the leading advisors for venture capital, private equity, and fund structuring in Germany. The firm and its partners have been recognized nationally and internationally by JUVE, Best Lawyers, Legal 500, Focus, Chambers and Partners as well as Leaders League. Today, YPOG has more than 150 experienced attorneys, tax advisors and tax specialists and a notary, in four offices, located in Berlin, Hamburg, Cologne, and Munich.





Further information: http://www.ypog.law and www.linkedin.com/company/ypog

Contact

Hanna Brand YPOG Partnerschaft von Rechtsanwälten und Steuerberatern mbB Schnittker + Partner Head of Corporate Communications T <u>+49 40 6077281 83</u> | E <u>presse@ypog.law</u> ypog.law

Benno Engelmann T +49 172 2749 689 | E <u>presse@ypog.law</u> Engelmann Advisory engelmann-advisory.com